Captivating bortezomib: an active but still mysterious drug.
作者信息
Di Raimondo Francesco, Conticello Concetta
出版信息
Leuk Res. 2010 Apr;34(4):411-2. doi: 10.1016/j.leukres.2009.09.021. Epub 2009 Oct 12.
Abstract
摘要
相似文献
1
Captivating bortezomib: an active but still mysterious drug.
Leuk Res. 2010 Apr;34(4):411-2. doi: 10.1016/j.leukres.2009.09.021. Epub 2009 Oct 12.
2
Gene mutation revelation points to new target for myeloma treatment, studies say.
J Natl Cancer Inst. 2007 Sep 19;99(18):1362-4. doi: 10.1093/jnci/djm164. Epub 2007 Sep 11.
3
Bortezomib data show improved survival in patients with relapsed multiple myeloma.
Oncology (Williston Park). 2004 Aug;18(9):1199, 1201.
4
[Proteasome inhibitor bortezomib as an anticancer drug].
Tanpakushitsu Kakusan Koso. 2006 Aug;51(10 Suppl):1251-6.
5
Proteasome inhibition in the treatment of cancer.
Cell Cycle. 2005 Feb;4(2):290-6. Epub 2005 Feb 3.
6
[Situation of translational research and development of molecular-targeted agents for multiple myeloma].
Nihon Rinsho. 2007 Dec;65(12):2357-61.
7
Use of bortezomib in B-cell non-Hodgkin's lymphoma.
Expert Rev Anticancer Ther. 2006 Jul;6(7):983-91. doi: 10.1586/14737140.6.7.983.
8
The role of bortezomib in the treatment of lymphoma.
Cancer Invest. 2007 Dec;25(8):766-75. doi: 10.1080/07357900701579570.
9
Bortezomib in multiple myeloma.
Best Pract Res Clin Haematol. 2007 Dec;20(4):701-15. doi: 10.1016/j.beha.2007.09.003.
10
Treatment of mantle cell lymphoma: targeting the microenvironment.
Expert Rev Anticancer Ther. 2005 Jun;5(3):477-85. doi: 10.1586/14737140.5.3.477.
Zotero 插件